Research Article

Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy

Dong-Mei Zhu,1,2 Jing Xie,1 Chun-Yan Ye,1,2 Mei-Yun Qian,1 and Yuan Xue1,2

1Department of Liver Diseases, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China
2Institute of Hepatology, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China

Correspondence should be addressed to Yuan Xue; xueyuan80908@163.com

Received 12 July 2020; Revised 30 November 2020; Accepted 8 December 2020; Published 18 December 2020

Academic Editor: Kevork M. Peltekian

Copyright © 2020 Dong-Mei Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. This study aimed to evaluate the risk factors of HCC development in patients with hepatitis B virus (HBV)-related DC and who underwent long-term antiviral therapy. Methods. Data from 308 patients with HBV-related DC and long-term antiviral therapy were collected and retrospectively reviewed. Cox regression analysis was used to analyze independent risk factors of HCC development. Results. Data from 129 patients with definite records were analyzed. The incidence of HCC was higher in males (30/78, 38.5%) than in females (11/51, 21.6%) (P = 0.04). Patients who developed HCC were significantly older than those who did not develop HCC (P < 0.01). The incidence of HCC in patients receiving nucleoside analogues, nucleotide analogues, and combination therapy was 34.7%, 38.1%, and 33.3%, respectively, and the difference showed no significant differences (P = 0.95). Multivariate Cox regression analysis demonstrated that male gender and age ≥50 years are independent risk factors of HCC development (OR = 2.987 and 2.408; 95% CI (1.301–6.858) and (1.126–5.149); P = 0.01 and 0.02, respectively). Conclusion. The risk of HCC remains to be high in patients with HBV-related DC, especially in males aged ≥50 years.

1. Introduction

Hepatitis B virus (HBV)-related liver cirrhosis (LC) leads to portal hypertension, hepatic dysfunction, and subsequent decompensation in individuals. Due to serious complications such as ascites, esophagogastic variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma (HCC), patients with decompensated cirrhosis (DC) had higher mortality than those with compensated LC [1]. Oral antiviral drugs such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) suppress HBV replication, improve liver function, and reduce mortality [2]. Despite long-term antiviral therapy, the risk of HCC persists over time according to a multicenter study conducted in Korea [3]. During the 5-year follow-up, 9.0% patients have developed HCC, while cumulative incidence of HCC for Caucasians with chronic hepatitis B (CHB) was 2.4% at age 8. Age, baseline LC status, and liver stiffness were shown to be risk factors of HCC [4]. However, studies on the risk factors for the development of HCC in patients with DC are rare.

Moreover, increasing evidence has revealed that TDF is superior over ETV in reducing HCC in patients with chronic HBV infection. Data from a study conducted in Korea have shown that the cumulative incidence rates of HCC in patients treated with TDF were lower than those treated with ETV, suggesting that TDF treatment significantly lowered the risk of HCC when compared to ETV [5]. Subsequently, three meta-analysis studies have reported similar findings [6–8]. Nevertheless, in another study, TDF was reported to be inferior over ETV in reducing HCC development [9]. To
our knowledge, the comparative effectiveness of nucleotide and nucleoside analogues in reducing the risk of HCC remains unclear in patients with DC.

We herein explored the cumulative incidence of HCC in patients with DC and long-term antiviral therapy through an 8-year follow-up and analyzed the risk factors associated with HCC development.

2. Patients and Methods

2.1. Patients. The data from 308 patients with HBV-related DC who were admitted to the Department of Liver Diseases, the Third People’s Hospital of Changzhou from January 2011 to January 2016, and received long-term antiviral therapy were retrospectively reviewed. DC in patients was diagnosed according to the China’s Guidelines for the Prevention and Treatment of Chronic Hepatitis B [10]: LC with at least one episode of ascites, jaundice, hepatic encephalopathy, or variceal bleeding. HCC was diagnosed based on imaging techniques, alpha-fetoprotein (AFP), tests, or biopsy [11]. Patients with malignant tumor and coinfection with other hepatitis virus were excluded from the study.

Demographic and clinical data, including age, gender, family history, clinical symptoms, and antiviral therapy, were collected. Laboratory data including hepatitis B e antigen (HBeAg) and HBV DNA, alanine aminotransferase (ALT), AFP, platelet counts, bilirubin, creatinine, and international standard ratio were collected at the time of admission. All patients with DC underwent abdominal ultrasonography, AFP, and biochemical tests at an interval of 3 to 6 months during the follow-up period. Patients who developed HCC within 6 months were excluded. The study endpoint included HCC development, death, or lost to follow-up. After HCC diagnosis, the patients were transferred to the Department of Oncology or Hepatobiliary Surgery and then underwent surgical resection, radiofrequency ablation, transarterial chemoembolization, or combination therapy according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 edition) [11]. This was a noninterventional study, and the study protocol was approved by the Ethics Committee of the Third People’s Hospital of Changzhou, according to the Declaration of Helsinki, 2013.

2.2. Statistical Analysis. SPSS 23.0 software (Chicago, IL, USA) was used for statistical processing. Continuous variables were expressed as means ± standard deviation or median (IQR), and categorical variables as frequencies. The data were then compared using Student’s t-test, Kruskal–Wallis test, or chi-square test. Kaplan–Meier curves were used to show the cumulative incidence of HCC, and multivariate Cox regression analysis was used to analyze the risk factors for HCC development. P values of <0.05 were considered to be statistically significant.

3. Results

3.1. Baseline Characteristics of Patients with HBV-Related DC. Among the 308 patients, 2 patients with malignant tumor were excluded, 11 patients died due to diseases other than HCC, 2 patients underwent liver transplantation, and 164 patients have lost to follow-up (Figure 1). Data from the remaining 129 patients with definite records were analyzed. The median follow-up time was 5 years (range, 1 to 8 years).

The baseline characteristics of 129 patients are presented in Table 1. More than half of the patients were males (78/129, 60.5%), with an average age of 53.81 years. Most of the patients (97/129, 75.2%) were HBeAg negative and had positive HBV DNA levels (80/129, 62.1%). Among the 129 patients, 72 patients received nucleosides monotherapy, 21 patients received nucleotides monotherapy, 15 patients received combination therapy with nucleosides and nucleotides, and the remaining 21 patients received sequential therapy with nucleosides and nucleotides.

Moreover, patients who were lost to follow-up had a higher model for end-stage liver disease (MELD) scores at baseline compared with patients followed up (P < 0.05). The proportions of patients with gastrointestinal bleeding were higher in patients who were lost to follow-up than those in patients followed up (P < 0.05) (Supplementary Table, available here).

3.2. Baseline Characteristics of Patients with HCC. At the end of the follow-up period, 41 patients developed HCC, and the cumulative incidence of HCC was 31.8%. The median time from diagnosing DC to the incidence of HCC was 4.4 years (range, 1–7 years). The incidence of HCC was higher in males (30/78, 38.5%) when compared to females (11/51, 21.6%) (χ2 = 4.059, P = 0.04).

HBV viral load at baseline and viral response at sixth months during antiviral therapy between HCC and no-HCC groups were compared, and the differences showed no statistical significance (t = −0.54, P = 0.56; χ2 = 0.26, P = 0.60).

Patients with developed HCC were significantly older than those who did not developed HCC (t = −4.482, P ≤ 0.001). The cutoff value of age according to MedCalc version 10.1 software for Windows (MedCalc software, Mariakerke, Belgium) was determined to be 50 years, and the incidence of HCC was compared using the Kaplan–Meier curve (P ≤ 0.001) (Figure 2). The results showed no significant differences in baseline platelet counts, creatinine, total bilirubin, serum sodium, AFP, and INR between the two groups (all P > 0.05).

Among the 60 patients with a family history of HBV infection, 15 (25.0%) developed HCC, while in 69 patients without family history, 26 (37.7%) developed HCC (χ2 = 0.639, P = 0.42). For 17 patients with a history of splenectomy, 5 developed HCC, while 36 of 112 patients without the history of splenectomy have developed HCC (χ2 = 0.051, P = 0.82).

Canadian Journal of Gastroenterology and Hepatology
With regard to the complications such as ascites, upper gastrointestinal bleeding, and hepatic encephalopathy, the incidence of HCC in patients with complications was similar to that in patients without complications ($\chi^2 = 0.000$, 1.907, and 0.888; $P = 0.99$, 0.27, and 0.35, respectively).

There were 129 patients who received antiviral therapy for more than a year. Of these, 72 patients received nucleoside analogues, including entecavir, lamivudine, and telbivudine, 21 patients received nucleotide analogues including adefovir and tenofovir, 15 patients received

| Age, years | Patients with HCC ($n = 41$) | Patients without HCC ($n = 88$) | $P$ value |
|------------|------------------------------|---------------------------------|-----------|
| Age $<50$ | 61 (53.5–66) | 51 (44.25–58.75) | $\leq 0.001$ |
| Male/female | 7/34 | 42/46 | $\leq 0.001$ | 0.04 |
| Complications, n (%) | | | |
| Encephalopathy | 6 (14.6) | 8 (9.1) | 0.35 |
| GI bleeding | 1 (2.4) | 8 (9.1) | 0.27 |
| Ascites | 21 (51.2) | 45 (51.1) | 0.94 |
| Splenectomy ($n = 17$) | 5 (12.2) | 12 (13.6) | 0.82 |
| Family history of CHB (Y/N) | 15/26 | 45/43 | 0.40 |
| Previous antiviral therapy | — | — | — |
| Nucleosides, n (%) | 25 (61.0) | 47 (53.4) | 0.29 |
| Nucleotides, n (%) | 8 (19.5) | 13 (14.8) | 0.60 |
| Combination therapy, n (%) | 5 (12.2) | 10 (11.3) | 0.68 |
| Sequential therapy, n (%) | 3 (7.3) | 18 (20.5) | 0.95 |
| Laboratory findings | | | |
| HBeAg positive, n (%) | 13 (31.7) | 19 (21.6) | 0.22 |
| HBV DNA (log IU/mL) | 4.17 ± 1.40 | 4.01 ± 1.64 | 0.59 |
| HBV DNA positive at 6th month, n (%) | 7 (17.0) | 12 (13.6) | 0.60 |
| ALT (U/L) | 57.29 ± 55.89 | 52.97 ± 47.14 | 0.68 |
| Total bilirubin (μmol/L) | 35.21 ± 18.43 | 35.53 ± 28.95 | 0.95 |
| Cholinesterase (U/L) | 4245.95 ± 1946.29 | 3653.83 ± 1655.46 | 0.12 |
| Platelet counts (E + 09/L) | 71.96 ± 49.01 | 81.97 ± 67.06 | 0.68 |
| INR | 1.30 ± 0.21 | 1.31 ± 0.33 | 0.82 |
| Sodium (mmol/L) | 140.83 ± 3.20 | 140.45 ± 2.5 | 0.49 |
| Creatinine (μmol/L) | 76.50 ± 17.00 | 75.77 ± 19.36 | 0.84 |
| AFP (ng/ml) | 3.28 (1.71–4.21) | 4.85 (2.36–19.70) | 0.14 |
| MELD | 11.63 ± 3.54 | 11.25 ± 4.56 | 0.64 |

Data are shown as means ± standard deviation or median (IQR). Abbreviations: HCC, hepatocellular carcinoma; GI, gastrointestinal; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid; ALT, alanine aminotransferase; INR, prothrombin time/international normalized ratio; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease.
combination treatment with nucleoside and nucleotide analogues, and the remaining 21 patients received sequential therapy with nucleosides and nucleotides. The incidence of HCC in these patients was 34.7%, 38.1%, 33.3%, and 10.3%, respectively, showing no significant differences among the four groups ($\chi^2 = 3.65, P = 0.29$).

3.3. Risk Factors for HCC Development in Patients with HBV-Related DC. Univariate and multivariate Cox regression analyses were conducted to determine the risk factors of HCC development. Univariate analysis showed that male gender ($P = 0.02$) and age $\geq 50$ years ($P = 0.04$) were found to be associated with HCC development. After that, multivariate Cox regression results revealed that male gender and age $\geq 50$ years are independent risk factors for HCC development (OR $= 2.987$ and $2.408$; 95% CI $(1.301–6.858)$ and $(1.126–5.149)$; $P = 0.01$ and $0.02$, respectively) (Table 2).

4. Discussion

In the present study, an 8-year follow-up was conducted to investigate the incidence of HCC development in patients with DC and long-term antiviral therapy. Data showed that 41 patients developed HCC, and the cumulative incidence of HCC was 31.8%. The median time from DC diagnosis to HCC incidence was 4.4 years. Multivariate Cox regression showed that male gender and age $\geq 50$ years are independent risk factors for HCC development.

The cumulative incidence of HCC was found to be 31.8%, which is much higher than the data reported from Korea and Europe countries [3, 4]. The main reason for the difference is that patients in the abovementioned studies have CHB or compensated LC, other than DC. Patients with HCC in the late stage have limited treatment strategies and poor prognosis, and so it is critical to detect HCC at an early stage. Patients with HBV-related DC are at high risk of HCC and should be screened for HCC in clinical practice.

Moreover, long-term antiviral therapy can result in biochemical remission and histological improvement, and even in the regression of cirrhosis, but the risk of HCC could not be eliminated, especially in patients with LC [12]. Jang et al. have reported that the incidence of HCC in patients who underwent antiviral-treated treatment and untreated DC was 32.3% and 27.2%, and antiviral therapy showed no significant effect on reducing the HCC incidence [13]. Patients with DC can benefit from maintained virologic response but had no significant reduction in the risk of HCC, or HCC-related mortality showed no significant reduction. Another study showed that no virologic response to entecavir ETV was a risk factor of HCC development in patients with DC [14]. Recently, HCC development in patients who received TDF and ETV treatments has attracted much attention worldwide, but data concerning HCC development in DC were scarce. In the present study, nucleosides and nucleotides showed no significant differences in HCC development in patients with DC. As a complement to previous studies [9, 13, 15–18], this suggests that nucleotide analogues might be not superior to nucleoside analogues in reducing HCC development in patients with HBV-related DC.

Recently, data from the U.S. Cancer Statistics Registry reported that the incidence of HCC has been increased in patients older than 50 years, and males are more prone to this [19]. Similar to the previous study [19], male gender and age $\geq 50$ years are considered as independent risk factors for HCC in patients with HBV-related DC. In addition, splenectomy showed no significant effect with regard to HCC incidence, and this is different from Lv’s study [20], requiring validation in a large sample size in the future.

However, the present study had some limitations. Almost half of the patients had lost to follow-up, and this was an inevitable but true limitation in this study. Since higher baseline MELD scores and higher proportions of patients with gastrointestinal bleeding were found in patients who were lost to follow-up, it can be speculated that many
Table 2: Risk factors for HCC development in patients with hepatitis B virus-related decompensated cirrhosis.

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | OR (95% CI)         | P value               | OR (95% CI) | P value |
| Age                | 2.994 (1.240–7.227) | 0.02                  | 2.987 (1.301–6.858) | 0.01 |
| Sex                | 2.561 (1.055–6.220) | 0.04                  | 2.408 (1.126–5.149) | 0.02 |
| ALT (U/L)          | 0.996 (0.987–1.005) | 0.35                  |              |
| Total bilirubin (µmol/L) | 1.006 (0.987–1.026) | 0.54                  |              |
| Cholinesterase (U/L) | 1.000 (0.999–1.000) | 0.50                  |              |
| Platelet counts (E + 09/L) | 1.000 (0.994–1.007) | 0.89                  |              |
| INR                | 1.00 (0.062–2.674)  | 0.35                  |              |
| Sodium (mmol/L)    | 1.122 (0.968–1.301) | 0.13                  |              |
| Creatinine (µmol/L) | 0.998 (0.978–1.0191) | 0.86                |              |
| AFP (ng/ml)        | 0.998 (0.998–1.002) | 0.77                  |              |

Abbreviations: ALT, alanine aminotransferase; INR, prothrombin time/international normalized ratio; AFP, alpha-fetoprotein.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yuan Xue was responsible for study design. Data collection was carried out by Dong-Mei Zhu, Yuan Xue, Jing Xie, Chun-Yan Ye, and Mei-Yun Qian. Data analysis was performed by Yuan Xue and Dong-Mei Zhu. Writing was done by Dong-Mei Zhu, Jing Xie, and Yuan Xue. All authors read and approved the final manuscript. Dong-Mei Zhu and Jing Xie contributed equally to this work.

Acknowledgments

This work was supported by grants from the Chinese Foundation for Hepatitis Prevention and Control-Tianqing Liver Disease Research Fund Subject, (TQGB20180378 and TQGB20190218), the Projects of Changzhou Science and Technology (CJ20190077), and the Applied Basic Research Projects from Science and Technology Bureau of Changzhou (CJ20179055).

Supplementary Materials

Supplementary table. Baseline characteristics of patients with decompensated Cirrhosis. (Supplementary Materials)

References

[1] European Association for the Study of the Liver, “EASL clinical practice guidelines for the management of patients with decompensated cirrhosis,” Journal of Hepatology, vol. 69, no. 2, pp. 406–460, 2018.
[2] M. L. Shiffman, “Approach to the patient with chronic hepatitis B and decompensated cirrhosis,” Liver International, vol. 40, no. S1, pp. 22–26, 2020.
[3] S. U. Kim, Y. S. Seo, H. A. Lee et al., “Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study,” Cancer Epidemiology, Biomarkers & Prevention, vol. 29, no. 4, pp. 832–837, 2020.
[4] G. V. Papatheodoridis, V. Sypsa, G. N. Dalekos et al., “Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B,” Journal of Hepatology, vol. 72, no. 6, pp. 1088–1096, 2020.
[5] J. Yurdakul, H. J. Kim, J. Lee, S. Cho, M. J. Ko, and Y.-S. Lim, “Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B,” JAMA Oncology, vol. 5, no. 1, pp. 30–36, 2019.
[6] M. Li, T. Lv, S. Wu et al., “Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis,” Hepatology International, vol. 14, no. 1, pp. 105–114, 2020.
[7] S. Wei, S. Park, M. H. Murad et al., “Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis,” Hepatology, 2020.
[8] W. M. Choi, J. Choi, and Y. S. Lim, “Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis,” Clinical Gastroenterology and Hepatology, 2020.
[9] G. V. Papatheodoridis, G. N. Dalekos, R. Idilman et al., “Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B,” Journal of Hepatology, vol. 73, no. 5, pp. 1037–1045, 2020.
[10] Chinese Society of Infectious Diseases, Chinese Society of Hepatology, and Chinese Medical Association, “The guidelines of prevention and treatment for chronic hepatitis B (2019 version),” Chin J Hepatol, vol. 27, no. 12, pp. 938–961, 2019.
[11] Sypsa’s of China and Department of Medical Administration, “Guidelines for diagnosis and treatment of primary liver
cancer in China (2019 edition),” *Chinese Journal of Hepatology*, vol. 28, no. 2, pp. 112–128, 2020.

[12] G. Grossi, M. Viganò, A. Loglio, and P. Lampertico, “Hepatitis B virus long-term impact of antiviral therapy nucleotide (s) ide analogues (NUCs),” *Liver International*, vol. 37, no. Suppl 1, pp. 45–51, 2017.

[13] J. W. Jang, J. Y. Choi, Y. S. Kim et al., “Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis,” *Hepatology*, vol. 61, no. 6, pp. 1809–1820, 2015.

[14] S. S. Woo, J. C. Hwang, S. G. Lim, S. J. Ahn, J. Y. Cheong, and S. W. Cho, “Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis,” *American Journal of Gastroenterology*, vol. 109, no. 8, pp. 1223–1233, 2014.

[15] J. W. Jang, J. Y. Choi, Y. S. Kim et al., “Effects of virologic response to treatment on short-and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis,” *Clinical Gastroenterology and Hepatology*, vol. 16, no. 12, pp. 1954–1963, 2018.

[16] Z. Yoo, Y. Hu, H. Wang et al., “Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy,” *European Journal of Gastroenterology & Hepatology*, vol. 32, no. 3, pp. 447–453, 2020.

[17] F. Wang, K. Berry, and G. N. Ioannou, “No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir,” *Gut*, 2020.

[18] I. Ha, J. W. Chung, E. S. Jang, S. H. Jeong, and J. W. Kim, “Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis,” *Journal of Gastroenterology and Hepatology*, vol. 35, no. 10, pp. 1774–1781, 2020.

[19] X. Zhang, H. B. El-Serag, and A. P. Thrift, “Sex and race disparities in the incidence of hepatocellular carcinoma in the United States examined through age-period-cohort analysis,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 29, no. 1, pp. 88–94, 2020.

[20] X. Lv, P. Yang, X. Guo et al., “Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis,” *Tumor Biology*, vol. 37, no. 7, pp. 8889–8900, 2016.